Lixte Biotechnology Holdings Stock Probability of Future Stock Price Finishing Over 32.47
| LIXT Stock | USD 1.98 0.07 3.66% |
Lixte |
Lixte Biotechnology Target Price Odds to finish over 32.47
The tendency of Lixte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 32.47 or more in 90 days |
| 1.98 | 90 days | 32.47 | close to zero percent |
Based on a normal probability distribution, the odds of Lixte Biotechnology to move over $ 32.47 or more in 90 days from now is close to zero percent (This Lixte Biotechnology Holdings probability density function shows the probability of Lixte Stock to fall within a particular range of prices over 90 days) . Probability of Lixte Biotechnology price to stay between its current price of $ 1.98 and $ 32.47 at the end of the 90-day period is about 26.38 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.06 . This indicates Lixte Biotechnology Holdings market returns are related to returns on the market. As the market goes up or down, Lixte Biotechnology is expected to follow. Additionally Lixte Biotechnology Holdings has an alpha of 0.4722, implying that it can generate a 0.47 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Lixte Biotechnology Price Density |
| Price |
Predictive Modules for Lixte Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lixte Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lixte Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lixte Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lixte Biotechnology is not an exception. The market had few large corrections towards the Lixte Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lixte Biotechnology Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lixte Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.47 | |
β | Beta against Dow Jones | 1.06 | |
σ | Overall volatility | 0.19 | |
Ir | Information ratio | 0.05 |
Lixte Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lixte Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lixte Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lixte Biotechnology is way too risky over 90 days horizon | |
| Lixte Biotechnology may become a speculative penny stock | |
| Lixte Biotechnology appears to be risky and price may revert if volatility continues | |
| Lixte Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Lixte Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: LIXT 3-Year Sharpe Ratio -0. - GuruFocus.com |
Lixte Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lixte Stock often depends not only on the future outlook of the current and potential Lixte Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lixte Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.9 M | |
| Cash And Short Term Investments | 4.2 M |
Lixte Biotechnology Technical Analysis
Lixte Biotechnology's future price can be derived by breaking down and analyzing its technical indicators over time. Lixte Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Lixte Biotechnology Holdings. In general, you should focus on analyzing Lixte Stock price patterns and their correlations with different microeconomic environments and drivers.
Lixte Biotechnology Predictive Forecast Models
Lixte Biotechnology's time-series forecasting models is one of many Lixte Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Lixte Biotechnology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Lixte Biotechnology
Checking the ongoing alerts about Lixte Biotechnology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lixte Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Lixte Biotechnology is way too risky over 90 days horizon | |
| Lixte Biotechnology may become a speculative penny stock | |
| Lixte Biotechnology appears to be risky and price may revert if volatility continues | |
| Lixte Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Lixte Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: LIXT 3-Year Sharpe Ratio -0. - GuruFocus.com |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.